KẾT QUẢ HOÁ TRỊ BỔ TRỢ PHÁC ĐỒ PEMETREXED - CISPLATIN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ

Abstract

Objectives: This study aimed to evaluate the clinical characteristics and treatment outcomes of the adjuvant chemotherapy regimen pemetrexed–cisplatin in patients with stage IB–IIIA non-small cell lung cancer after surgery. Patients and methods: This is a retrospective and prospective descriptive study, conducted on 38 patients with stage IB–IIIA NSCLC who received adjuvant chemotherapy with pemetrexed–cisplatin after complete surgical resection at Hanoi Medical University Hospital and Hung Vuong Hospital from January 2020 to December 2024. Results: The average age was 61.2 ± 8.8 years; 78.9% of the patients were male, and 68.4% had a history of smoking. All patients had a performance status (PS) of 0–1. Adenocarcinoma was the most common type, accounting for 97.4%. A total of 78.9% of patients completed all 4 chemotherapy cycles. No patients stopped treatment due to toxicity. The median disease-free survival (DFS) was 29 months (95% CI: 23.7–34.2). The 1-year and 2-year DFS rates were 94.7% and 82.6%, respectively. At the time of analysis, no relapse was recorded in patients with stage IB. Most side effects were mild, and no grade 3–4 toxicity was reported. Conclusion: The pemetrexed–cisplatin regimen showed promising disease-free survival and good tolerability in clinical practice. Further studies with larger sample sizes are needed to confirm these results.